30th Annual PPMD Conference

Orlando, Florida | June 29, 2024

satellos

Muscle regeneration: the next horizon™

Legal Disclaimers

Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always using words or phrases such as “expect”, “seek”, “endeavor”, “anticipate”, “plan”, “estimate”, “believe”, “intend”, or stating that certain actions, events or results may, could, would, might or will occur or be taken, or achieved) are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which would cause actual results or events to differ materially from those presently anticipated. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made and involve significant known and unknown risks, uncertainties and assumptions. A number of factors could cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. These include, but are not limited to, risks regarding the pharmaceutical industry, market conditions, economic factors, management’s ability to manage and operate the business of Satellos and the equity markets generally. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements could vary materially from those expressed or implied by the forward-looking statements contained in this document. These factors should be considered carefully. Existing or prospective investors should not place undue reliance on these forward-looking statements. Although the forward-looking statements contained in this document are based upon what Satellos Bioscience Inc. (“Satellos”) currently believes to be reasonable assumptions, Satellos cannot assure recipients that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Satellos does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances.

This presentation is for information only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities in any jurisdiction. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual’s circumstances are different. Investors should consult with their own professional advisors regarding their particular circumstances.

The information contained herein is subject to change without notice and is based on publicly available information, internally developed data and other sources. Where any opinion or belief is expressed in this presentation, it is based on the assumptions and limitations mentioned herein and is an expression of present opinion or belief only. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. The public disclosure records of Satellos are expressly not incorporated by reference into this presentation. Satellos disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it. The industry data, forecasts and other information prepared by third parties presented in this presentation, except where otherwise noted, has been compiled from industry sources and participants which, although not independently verified by Satellos, are considered by Satellos to be reliable sources of information. References in this presentation to reports or articles should not be construed as depicting the complete findings of the entire referenced report or article and such report or article is expressly not incorporated by reference into this presentation. Satellos makes no representation or warranty as to the accuracy or completeness of any data or information prepared by third parties included in this presentation and Satellos assumes no liability whatsoever relating to or resulting from such data or information or the use thereof, errors therein or omissions therefrom.

Satellos is based on a landmark discovery

Duchenne is also a **stem cell** disease

New muscle cells are not being created as needed for ongoing fiber repair and regeneration, resulting in muscle being lost.

What this means for patients

- Potential for a new treatment intended to bring muscle back


What Satellos is doing about it

- We invented an oral tablet, **SAT-3247**, to **regenerate muscle**

Satellos' Scientific Founder and Chief Discovery Officer



Michael Rudnicki, OC, PhD, FRS, FRSC



nature medicine

Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division

Nicolas A Dumont[1,2,4], Yu Xin Wang[1,2,4], Julia von Maltzahn[1–3], Alessandra Pasut[1,2], C Florian Bentzinger[1–3], Caroline E Brun[1,2] & Michael A Rudnicki[1,2]

satellos

© 2024 Satellos Bioscience

SAT-3247: A pill to regenerate muscle

Dystrophin Independent

Oral medicine to restore **muscle regeneration**



Dystrophin Dependent

Genetic medicines to stabilize **muscle fibers**




Satellos expects **SAT-3247** to have potential to safely treat all patients regardless of other medications, including as ADD-ON to gene therapy!

satellos

© 2024 Satellos Bioscience

Satellos discovery confirmed in Duchenne patients



- Clinical reports show that Duchenne patients have muscle stem cells
- **As we discovered in Mdx mice, there are not enough progenitor muscle cells**
- Thus, muscle fibers cannot repair themselves in response to typical wear and tear


SAT-3247 designed to restore muscle repair by resetting progenitor cell production


satellos

* Kottlers et al 2010

© 2024 Satellos Bioscience

Muscle stem cells need a *'signal'* from dystrophin to repair and regenerate muscle fibers







satellos

© 2024 Satellos Bioscience

Muscle stem cells need a *'signal'* from dystrophin to repair and regenerate muscle fibers






SAT-3247 resets progenitor cell production by replacing the missing *'signal'*

satellos

© 2024 Satellos Bioscience


SAT-3247 resets progenitor cell production and increases muscle force, a result of regeneration

In vitro
MyoReGenX™(1)



3247 **increases progenitors**

In vivo (Mdx)
28-day Treatment with SAT-3247



3247 **increases muscle force**

1. MyoReGenX is Satellos' proprietary discovery platform

satellos


© 2024 Satellos Bioscience

Preliminary SAT-3247 results show improvements in canine model of DMD (*interim data from pilot study**)


Regenerative status

4-months of dosing with SAT-3247

IgG+ve (damage)





Pre-SAT-3247 Post-SAT-3247



Muscle force

2-months of dosing with SAT-3247






SAT-3247 appears to repair muscle and increase strength in canine model of DMD

satellos

© 2024 Satellos Bioscience

* Preliminary results from individual dog from a pilot study of two dogs

SAT-3247 is about to enter clinical trials



We will work with PPMD to share trial information and recruitment opportunities. In the meantime, please visit www.satellos.com for updates

satellos

© 2024 Satellos Bioscience

Satellos has built an outstanding, experienced team to develop SAT-3247



Frank Gleeson, MBA
Co-Founder &
Chief Executive Officer



Liz Williams, CPA, CA
Chief Financial Officer



Philip Lambert, PhD
Chief Scientific Officer



Michael Cross, PhD, MBA
Chief Business Officer



Courtney Wells
SVP Clinical Dev. Operations



Michael Rudnicki, OC, PhD, FRS
Co-Founder &
Chief Discovery Officer

Clinical Advisory Board

Jordan Dubow, M.D.
Chair, CAB and Chief Medical Advisor,
Satellos Bioscience

Ronald Cohn, M.D., Ph.D.
President and CEO, Hospital for
Sick Children, Toronto

Richard Finkel, M.D.
Director, Center for Experimental Neurotherapeutics,
St. Jude Children's Research Hospital

Nicholas Johnson, M.D., MSCI, FAAN
Division Chief of Neuromuscular,
Virginia Commonwealth University

Hanns Lochmüller, M.D., Ph.D.
Senior Scientist, Children's Hospital of
Eastern Ontario Research Institute

Francesco Muntoni, M.D., Ph.D.
Director, Dubowitz Neuromuscular Centre, Great
Ormond Street UCL Institute of Child Health

Perry Shieh, M.D., Ph.D., FAAN
Professor of Neurology, UCLA David Geffen
School of Medicine

satellos

© 2024 Satellos Bioscience

REIMAGINE how muscle degeneration is treated.

REGENERATE with small molecule medicines.

REALIZE the *next* horizon to improve lives.

Thank you to:

Parent Project Muscular Dystrophy

satellos